Neoprobe Lymphoseek trial moves forward

Gamma camera probe developer Neoprobe said that results from the first stage of a multicenter phase II clinical study of its Lymphoseek radioactive tracing agent support enrollment in the second stage of the study.

The study is evaluating the efficacy and safety of Lymphoseek in patients with either melanoma or breast cancer, according to the Dublin, OH-based firm. In the second stage of the study, an additional 40 patients with either melanoma or breast cancer will be enrolled at all five of the U.S. cancer centers participating in the study, Neoprobe said.

By staff writers
March 5, 2007

Related Reading

Neoprobe gets FDA nod for more Lymphoseek trials, January 17, 2007

Neoprobe debuts Bluetooth probe, October 10, 2006

Neoprobe, Estech ink distribution deal, September 11, 2006

Neoprobe to start Lymphoseek trial, July 13, 2006

Neoprobe, Estech ink deal, June 8, 2006

Copyright © 2007

Page 1 of 436
Next Page